Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer

• Hoofdauteurs: M.ª Echave (Auteur), C. Pericay (Auteur), C. Frías (Auteur), A. Abad (Auteur), M.ª J. Lamas (Auteur), I. Oyagüez (Auteur), M. Rubio (Auteur), E. Giménez (Auteur), S. Naoshy (Auteur), F. Joulain (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2014-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin. Methods: Based on clinical trial VELOUR results, a three-state Markov model...